샘플 요청 목록

 카트 문의
시장보고서
상품코드
1761115

세계의 의약품 위탁생산 시장

Pharmaceutical Contract Manufacturing
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 528 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

의약품 위탁생산 세계 시장은 2030년까지 1,596억 달러에 달할 전망

2024년에 1,178억 달러로 추정되는 의약품 위탁생산 세계 시장은 2024년부터 2030년까지 CAGR 5.2%로 성장하여 2030년에는 1,596억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 의약품은 CAGR 5.9%를 기록하며 분석 기간 종료시에는 938억 달러에 달할 것으로 예상됩니다. 바이오의약품 부문의 성장률은 분석 기간 동안 CAGR 4.3%로 추정됩니다.

미국 시장은 354억 달러로 추정, 중국은 CAGR 6.3%로 성장 예측

미국의 의약품 위탁생산 시장은 2024년에 354억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 269억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.3%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.1%와 4.7%로 예측됩니다. 유럽에서는 독일이 CAGR 4.7%로 성장할 것으로 예측됩니다.

세계의 의약품 위탁생산 시장 - 주요 동향과 촉진요인 정리

의약품 위탁생산이란 무엇이며, 왜 필수적인가?

의약품 위탁생산이란 의약품의 제조를 제3의 기관에 위탁하는 것을 말합니다. 이 비즈니스 모델을 통해 제약회사는 신약개발, 시장개척, 마케팅 등 핵심 역량에 집중할 수 있고, 위탁생산업체(CMO)는 엄격한 규제기준 준수를 포함한 복잡한 제조업무를 처리할 수 있습니다. 이러한 파트너십은 제조 시설에 투자할 인프라와 자본이 부족할 수 있는 중소규모의 생명공학 기업에게 매우 중요합니다. 또한, 대형 제약사들도 유연성을 높이고, 비용을 관리하고, 신약 출시 시간을 단축하기 위해 이 모델을 활용하고 있습니다.

세계 규제는 어떻게 시장을 형성하고 있는가?

FDA(미국 식품의약국), EMA(유럽의약품청) 및 기타 세계 규제 기관의 엄격한 가이드라인으로 인해 규제 준수는 의약품 위탁 제조의 매우 중요한 측면이 되었습니다. 이러한 규제는 의약품이 일관되게 제조되고 품질 기준에 따라 관리되도록 보장합니다. 계약 제조업체는 이러한 변화하는 규제에 적응해야 하며, 규정 준수를 보장하기 위해 기술 및 프로세스에 많은 투자를 해야 하는 경우가 많습니다. 규제 압력이 증가함에 따라 제약사들은 복잡한 규제 상황을 극복하고 의약품의 안전성, 유효성 및 품질을 보장할 수 있는 CMO에 대한 의존도를 높이고 있습니다.

위탁생산에 영향을 미치는 기술 발전은 무엇인가?

기술의 발전은 의약품 위탁 제조를 크게 변화시키고 있습니다. 생산을 간소화하고 효율성을 향상시키는 연속 생산과 같은 기술 혁신이 널리 보급되고 있습니다. 또한 생산 공정의 정확성을 높이고 인적 오류를 줄이기 위해 자동화 및 로봇 공학도 널리 채택되고 있습니다. 또한, 전체 제조 공정의 품질 관리를 보장하기 위해 고도의 분석 및 실시간 모니터링 시스템이 도입되고 있습니다. 이러한 기술은 제품의 품질을 향상시킬 뿐만 아니라 낭비를 줄이고 확장성을 높여 생산 공정을 보다 비용 효율적이고 효율적으로 만듭니다.

의약품 위탁생산 시장의 성장 원동력은?

의약품 위탁생산 시장의 성장은 제네릭 의약품에 대한 수요 증가, 의약품 제조의 복잡성 증가, 생물학적 제제 시장의 확대 등 여러 가지 요인으로 인해 발생합니다. 특허 절벽이 제네릭 의약품의 경쟁 심화로 이어지면서 제약기업들은 생산 속도를 높이고 시장 기회를 활용하기 위해 시장 경쟁을 중시하고 있습니다. 또한 차세대 의약품, 특히 생물학적 제제 및 맞춤형 의약품의 제조는 복잡하기 때문에 전문적인 역량이 필요하며 많은 제약기업은 아웃소싱이 더 현실적이라고 생각합니다. 또한, 맞춤형 의료로의 전환으로 인해 기업들은 유연하고 확장 가능한 생산 공정에 적응해야 하며, 위탁 제조 업체는 이에 대응할 수 있는 능력을 갖추고 있습니다. 이러한 추세는 비용 효율성과 시장 출시 시간 단축을 추구하는 전 세계적인 움직임과 함께 제약 산업의 공급망에서 중요한 역할을 강조하며, 이 분야의 상당한 성장을 주도하고 있습니다.

부문

제품 유형(API/벌크 드러그, 첨단 약물전달 제제, 패키징, 완성 용량 제제, 기타 제품 유형), 용도(의약품, 바이오의약품), 최종 용도(무균, 비무균)

조사 대상 기업 사례(총 192개사)

  • AbbVie Inc.
  • Aenova Holding GmbH
  • Catalent Inc.
  • Enteris BioPharma, Inc.
  • Jubilant Pharma Ltd.
  • Kemwell Biopharma Pvt. Ltd.
  • Lifecore Biomedical
  • Lonza Group Ltd.
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec Co., Ltd.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 인도
  • 기타 아시아태평양
  • 기타 지역

제4장 경쟁

ksm

Global Pharmaceutical Contract Manufacturing Market to Reach US$159.6 Billion by 2030

The global market for Pharmaceutical Contract Manufacturing estimated at US$117.8 Billion in the year 2024, is expected to reach US$159.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$93.8 Billion by the end of the analysis period. Growth in the Biopharmaceutical segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$35.4 Billion While China is Forecast to Grow at 6.3% CAGR

The Pharmaceutical Contract Manufacturing market in the U.S. is estimated at US$35.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$26.9 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Pharmaceutical Contract Manufacturing Market - Key Trends & Drivers Summarized

What Is Pharmaceutical Contract Manufacturing, and Why Is It Essential?

Pharmaceutical contract manufacturing involves outsourcing the production of pharmaceutical products to third-party organizations. This business model allows pharmaceutical companies to focus on their core competencies such as drug discovery, development, and marketing, while contract manufacturers (CMOs) handle the complexities of production, including compliance with stringent regulatory standards. This partnership is crucial for small and mid-sized biotech firms that may lack the infrastructure or capital to invest in manufacturing facilities. Moreover, even large pharmaceutical companies leverage this model to enhance flexibility, manage costs, and reduce time to market for new medications.

How Are Global Regulations Shaping the Market?

Regulatory compliance is a pivotal aspect of pharmaceutical contract manufacturing, with stringent guidelines set by authorities like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other global regulatory bodies. These regulations ensure that pharmaceutical products are consistently produced and controlled to quality standards. Contract manufacturers must adapt to these evolving regulations, which often involve substantial investments in technology and processes to ensure compliance. As regulatory pressures increase, pharmaceutical companies are increasingly relying on CMOs that can navigate complex regulatory landscapes, thus ensuring the safety, efficacy, and quality of pharmaceutical products.

What Technological Advances Are Impacting Contract Manufacturing?

Technological advancements are profoundly transforming pharmaceutical contract manufacturing. Innovations such as continuous manufacturing, which streamlines production and improves efficiency, are becoming more prevalent. Automation and robotics have also been widely adopted to enhance precision and reduce human error in production processes. Additionally, advanced analytics and real-time monitoring systems are being implemented to ensure quality control throughout the manufacturing process. These technologies not only improve product quality but also reduce waste and enhance scalability, making the production process more cost-effective and efficient.

What Drives the Growth in the Pharmaceutical Contract Manufacturing Market?

The growth in the pharmaceutical contract manufacturing market is driven by several factors, including the rising demand for generic medicines, the increasing complexity of drug production, and the expansion of the biologics market. As patent cliffs lead to increased generic competition, pharmaceutical companies are turning to CMOs to expedite production and capitalize on market opportunities. The complexity of producing new generations of drugs, especially biologics and personalized medicines, also necessitates specialized capabilities that many pharmaceutical firms find more feasible to outsource. Additionally, the shift towards personalized medicine is pushing companies to adapt to flexible and scalable production processes, which contract manufacturers are equipped to handle. These trends, combined with the global push for cost efficiency and faster time-to-market, continue to drive significant growth in this sector, highlighting its critical role in the pharmaceutical industry’s supply chain.

SCOPE OF STUDY:

The report analyzes the Pharmaceutical Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations, Other Product Types); Application (Pharmaceutical, Biopharmaceutical); End-Use (Sterile, Non-Sterile)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; India; Rest of Asia-Pacific; Rest of World.

Select Competitors (Total 192 Featured) -

  • AbbVie Inc.
  • Aenova Holding GmbH
  • Catalent Inc.
  • Enteris BioPharma, Inc.
  • Jubilant Pharma Ltd.
  • Kemwell Biopharma Pvt. Ltd.
  • Lifecore Biomedical
  • Lonza Group Ltd.
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Pharmaceutical Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Strong Rise in Pharmaceutical Sales to Drive Demand for Pharmaceutical Contract Manufacturing
    • Global Prescription Drug Sales (In US$ Billion) for the Years 2017, 2019, 2021, 2023 & 2025
    • Emergence of Outsourcing Trend Bodes Well for CDMOs
    • Pharmaceutical Contract Manufacturers Adopt Advanced Manufacturing Technologies
    • Embracing Emerging Technologies
    • Exploring & Exploiting New Technologies for Rich Dividends
    • Rapid Growth of Generic Drugs Drives Demand for Pharma Contract Manufacturing
    • Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
    • Increasing Significance of Biologic Drugs Fuels Innovations Supports Demand for Pharmaceutical Contract Manufacturing Market
    • Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
    • Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Persistent Increase in Pharmaceutical R&D Bodes Well for PCM
    • Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
    • Increasing Sales of OTC Drugs Presents an Opportunity for Pharma Contract Manufacturing Market
    • Increasing Outsourcing of Clinical Trials to Emerging Markets
    • New Technology Promises to Improve Sterile Manufacturing Process
    • Serialization Drives New Design Developments in Pharma Sector
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 3: World 16-Year Perspective for API/Bulk Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 6: World 16-Year Perspective for Advanced Drug Delivery Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 9: World 16-Year Perspective for Packaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 12: World 16-Year Perspective for Finished Dose Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 18: World 16-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 21: World 16-Year Perspective for Biopharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 24: World 16-Year Perspective for Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 27: World 16-Year Perspective for Non-Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 28: World Pharmaceutical Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • JAPAN
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • CHINA
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • EUROPE
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
  • FRANCE
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • GERMANY
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for India and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • INDIA
    • Pharmaceutical Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 137: India Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: India Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: India 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 140: India Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: India Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: India 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 143: India Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: India Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: India 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Asia-Pacific 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 155: Rest of World Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of World 16-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of World 16-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of World Recent Past, Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of World 16-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제